Symptoms
Common signs and symptoms of Thrombotic Thrombocytopenic Purpura include:
When to see a doctor
If you experience severe or worsening symptoms, seek immediate medical attention. Always consult with a healthcare professional for proper diagnosis and treatment.
Causes & Risk Factors
Several factors can contribute to Thrombotic Thrombocytopenic Purpura.
TTP develops when the body lacks enough of a specific enzyme called ADAMTS13, which normally breaks down large clumps of a blood protein called von Willebrand factor.
TTP develops when the body lacks enough of a specific enzyme called ADAMTS13, which normally breaks down large clumps of a blood protein called von Willebrand factor. Think of ADAMTS13 as molecular scissors that cut up sticky protein strands in the blood. When these scissors don't work or aren't present in sufficient quantities, the sticky proteins accumulate and trap platelets, forming microscopic clots throughout the circulatory system.
The enzyme deficiency happens in two main ways.
The enzyme deficiency happens in two main ways. Hereditary TTP occurs when people inherit genetic mutations that prevent their bodies from making enough ADAMTS13 from birth. This form typically appears in infancy or early childhood, though some cases don't manifest until adulthood during times of stress like pregnancy or infection.
Acquired TTP, the more common form, develops when the immune system mistakenly creates antibodies that attack and destroy the ADAMTS13 enzyme.
Acquired TTP, the more common form, develops when the immune system mistakenly creates antibodies that attack and destroy the ADAMTS13 enzyme. This autoimmune reaction can be triggered by various factors including certain medications, infections, pregnancy, cancer, or autoimmune diseases. Sometimes the trigger remains unknown, making acquired TTP particularly unpredictable and challenging to prevent.
Risk Factors
- Female gender, especially during reproductive years
- Pregnancy or recent childbirth
- Autoimmune diseases like lupus or rheumatoid arthritis
- Certain medications including chemotherapy drugs
- Recent infections, particularly bacterial or viral
- Family history of TTP or related blood disorders
- Cancer, especially blood cancers
- Recent surgery or major medical procedures
- HIV infection
- Organ transplantation with immunosuppressive therapy
Diagnosis
How healthcare professionals diagnose Thrombotic Thrombocytopenic Purpura:
- 1
Diagnosing TTP requires a combination of clinical observation and specialized laboratory tests, as no single test can definitively confirm the condition.
Diagnosing TTP requires a combination of clinical observation and specialized laboratory tests, as no single test can definitively confirm the condition. Doctors typically start by examining the classic pentad of symptoms: low platelet count, destruction of red blood cells, neurological symptoms, fever, and kidney problems. However, many patients don't present with all five features, making diagnosis more challenging.
- 2
Blood tests form the cornerstone of TTP diagnosis.
Blood tests form the cornerstone of TTP diagnosis. A complete blood count reveals low platelets and signs of hemolytic anemia, where red blood cells are being destroyed faster than normal. The blood smear under a microscope shows characteristic fragmented red blood cells called schistocytes, which look like they've been chopped up by tiny clots. The most specific test measures ADAMTS13 enzyme activity and looks for antibodies against this enzyme.
- 3
Doctors must also rule out other conditions that can cause similar symptoms, including hemolytic uremic syndrome, disseminated intravascular coagulation, and certain autoimmune diseases.
Doctors must also rule out other conditions that can cause similar symptoms, including hemolytic uremic syndrome, disseminated intravascular coagulation, and certain autoimmune diseases. Additional tests might include kidney function studies, liver enzymes, and heart function assessments to evaluate how extensively the condition has affected various organ systems. Given TTP's potential for rapid deterioration, many doctors begin treatment based on strong clinical suspicion rather than waiting for all test results to return.
Complications
- TTP can cause serious complications affecting multiple organ systems due to the widespread formation of microscopic clots.
- Neurological complications are among the most concerning and can include stroke, seizures, persistent cognitive problems, and in severe cases, coma.
- These brain-related issues occur when tiny clots block blood flow to different areas of the brain, potentially causing permanent damage if treatment is delayed.
- Kidney problems develop when clots interfere with normal kidney filtration, potentially leading to acute kidney injury or, in rare cases, permanent kidney damage requiring dialysis.
- Heart complications can include heart attack or heart rhythm abnormalities, while lung involvement may cause difficulty breathing or acute lung injury.
- Most of these complications improve with successful treatment of the underlying TTP, though some patients may experience lasting effects, particularly if treatment was delayed or if they had severe disease.
Prevention
- Primary prevention of TTP remains largely impossible since most cases develop unpredictably, especially the acquired autoimmune form.
- However, people with known risk factors can take steps to reduce their likelihood of triggering an episode.
- Those with autoimmune diseases should work closely with their doctors to keep their conditions well-controlled, as active inflammation may increase TTP risk.
- For individuals who have survived a TTP episode, preventing recurrence becomes a priority.
- This involves avoiding known triggers when possible, maintaining good overall health, and staying alert for early warning signs.
- Some patients benefit from regular monitoring of their ADAMTS13 levels and platelet counts, especially during high-risk periods like pregnancy or illness.
- Prompt treatment of infections and careful medication management help reduce the risk of triggering another episode.
- Patients with hereditary TTP may benefit from prophylactic plasma infusions during high-risk situations like surgery, pregnancy, or severe illness.
- Genetic counseling can help families understand inheritance patterns and make informed decisions about family planning.
Plasma exchange therapy serves as the primary treatment for TTP and often makes the difference between life and death.
Plasma exchange therapy serves as the primary treatment for TTP and often makes the difference between life and death. This procedure removes the patient's plasma, which contains the harmful antibodies and damaged proteins, replacing it with fresh donor plasma that contains healthy ADAMTS13 enzyme. Most patients require daily plasma exchange sessions until their platelet count normalizes and other symptoms improve, typically taking one to two weeks.
Corticosteroids like prednisone help suppress the immune system's attack on the ADAMTS13 enzyme and are usually given alongside plasma exchange therapy.
Corticosteroids like prednisone help suppress the immune system's attack on the ADAMTS13 enzyme and are usually given alongside plasma exchange therapy. For patients who don't respond to initial treatment or experience relapses, doctors may prescribe rituximab, a medication that targets specific immune cells producing the harmful antibodies. This treatment has significantly improved outcomes for people with difficult-to-treat TTP.
Supportive care addresses the various complications that can arise during treatment.
Supportive care addresses the various complications that can arise during treatment. Patients may need blood pressure management, careful fluid balance monitoring, and protection from bleeding due to low platelet counts. Platelet transfusions are generally avoided in TTP unless there's life-threatening bleeding, as they can potentially worsen the condition by providing more material for clot formation.
Newer treatments show promise for the future of TTP management.
Newer treatments show promise for the future of TTP management. Caplacizumab, a medication that prevents platelets from clumping together, has been approved in some countries and can reduce the time needed for plasma exchange. Researchers are also investigating other immune-modulating therapies and enzyme replacement options that could make treatment more targeted and effective.
Living With Thrombotic Thrombocytopenic Purpura
Living with TTP requires ongoing vigilance and lifestyle adjustments, especially for those who have experienced multiple episodes. Patients need to become experts at recognizing early warning signs like unusual fatigue, new bruising, or changes in thinking, as prompt medical attention can prevent serious complications. Many people benefit from wearing medical alert jewelry and carrying information about their condition, since TTP is rare and emergency room doctors may not immediately recognize it.
Latest Medical Developments
Latest medical developments are being researched.
Frequently Asked Questions
Update History
Apr 3, 2026v1.0.0
- Published by DiseaseDirectory